🍪 CompoundTalk uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsInternationalNew Zealand Medsafe — GLP-1 scheduling and Pharmac funding Page 4

New Zealand Medsafe — GLP-1 scheduling and Pharmac funding

pat_auckland Thu, Mar 5, 2026 at 12:45 AM 18 replies 668 viewsPage 4 of 4
PurityPaulOR
Senior Member
1,890
7,890
Mar 2024
Oregon
Mar 5, 2026 at 6:25 AM#16

Just wanted to say — for anyone reading this New Zealand Medsafe thread who is feeling discouraged: it gets better. The first few weeks are the hardest. Hang in there. 💪

9 0Dr.LeslieOBGYN, MikeNYC_runner and 6 others
Reply Quote Save Share Report
RunnerRach
Member
467
2,123
Aug 2024
Boston, MA
Mar 5, 2026 at 6:42 AM#17

pat_auckland's experience with New Zealand Medsafe resonates deeply with mine. I went through almost the identical process — starting dose, titration timeline, side effects, everything.

The main difference: I titrated faster. But the overall trajectory has been remarkably similar. Down 64 lbs in 9 months.

One thing I would add that pat_auckland did not mention: the relationship with food fundamentally changed.

6 15MikeKY_noInsulin, Dr.RaviCardio, jennifer_SEA and 3 others
Reply Quote Save Share Report
dave_SLC
Member
345
1,567
Aug 2024
Salt Lake City, UT
Mar 5, 2026 at 6:59 AM#18

Saving this for reference. Quality thread.

17 12james_edin, FranDenver, Dr.BariatricHTX and 14 others
Reply Quote Save Share Report

PeptideMeter — Independent Peptide Analytics

Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.

View Results
Dr.ReproEndo
Senior Member
1,890
8,901
Jan 2024
Scottsdale, AZ
Mar 5, 2026 at 7:16 AM#19

As a healthcare provider, I want to add some clinical context to this discussion on New Zealand Medsafe GLP-1 scheduling.

Building on what pat_auckland said — the evidence base here is well-established. The key publications to reference are from the SURMOUNT program[1].

Key clinical points:

  1. Efficacy is dose-dependent and typically requires 4-5 weeks to reach steady state
  2. Side effect profile is predictable and usually manageable with standard protocols
  3. Monitoring should include baseline labs and follow-up at 3-month intervals
  4. Patient education significantly improves outcomes and adherence

Standard disclaimer: this is educational, not individualized medical advice.

References:
[1] See thread title for relevant study identification.
Last edited: Mar 5, 2026 at 8:16 AM
15 0GraceAZ_72, carl_compliance, DanielChem_CHI and 12 others
Reply Quote Save Share Report
sean_dublin
Member
212
890
Nov 2024
Dublin, IE
Mar 5, 2026 at 7:33 AM#20

Subscribing to this thread. New Zealand Medsafe is exactly what I've been researching. 🙏

15 6quinn_sf, NurseLeah_Nash, gary_naperville and 12 others
Reply Quote Save Share Report

Similar Threads

EU EMA compounding guidance — 2026 regulatory update9 replies
UK NHS GLP-1 prescribing — NICE TA875 and access guide7 replies
Australian TGA scheduling changes — peptide access 20268 replies
Canadian GLP-1 coverage — provincial formulary comparison6 replies
Purchasing GLP-1 in Mexico — legality, quality, and safety concerns6 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register